文献速递瓣膜病与结构性心脏病

经导管主动脉瓣置换术等待时间的时间趋势与临床后果:一项基于人群的研究

Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement: A Population-Based Study.
PubMed 文献 · Circulation · 2018-01-01

该研究纳入加拿大安大略省2010年4月1日至2016年3月31日所有经导管主动脉瓣置换术(TAVR)转诊病例,评估等待时间的时间趋势及临床后果。结果显示报销后等待时间中位数稳定在80天,等待期间死亡和心衰住院的累积概率分别约2%和12%,提示当前等待时间与显著疾病负担相关,需增加服务能力。

要点

  • TAVR报销后等待时间中位数稳定在80天,未再缩短。
  • 等待80天时全因死亡累积概率约2%,心衰住院约12%。
  • 等待时间延长与事件风险持续增加相关,需提升服务容量。

核心结论

  • 报销后TAVR等待时间未见改变,提示服务能力增长与需求增长同步,但近3个月的等待仍伴随显著疾病负担。

研究设计与样本

  • 基于加拿大安大略省的人群研究,纳入2010年4月1日至2016年3月31日所有TAVR转诊,共4461例。
  • 采用分段回归分析评估2012年9月省级报销前后TAVR等待时间的时间趋势。

主要发现

  • 4461例转诊中,50%接受了TAVR,39%因其他原因退出等待名单,11%在研究结束时仍在等待。
  • 接受TAVR的患者报销后估计中位等待时间稳定在80天且保持不变。
  • 等待80天时全因死亡和心衰住院的累积概率分别约为2%和12%,事件随等待时间延长呈相对恒定增加。

临床怎么用

  • 临床转诊TAVR时应关注等待期间死亡和心衰住院风险,尤其等待接近80天时。
  • 医疗系统需评估服务容量与转诊需求匹配,以缩短等待时间并降低等待期事件。

局限性

  • 研究为观察性设计,可能受未测量混杂因素影响。
  • 结果基于加拿大安大略省单一支付体系人群,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Transcatheter aortic valve replacement (TAVR) represents a paradigm shift in the therapeutic options for patients with severe aortic stenosis. However, rapid and exponential growth in TAVR demand may overwhelm capacity, translating to inadequate access and prolonged wait times. Our objective was to evaluate temporal trends in TAVR wait times and the associated clinical consequences. METHODS: In this population-based study in Ontario, Canada, we identified all TAVR referrals from April 1, 2010, to March 31, 2016. The primary outcome was the median total wait time from referral to procedure. Piecewise regression analyses were performed to assess temporal trends in TAVR wait times, before and after provincial reimbursement in September 2012. Clinical outcomes included all-cause death and heart failure hospitalizations while on the wait list. RESULTS: The study cohort included 4461 referrals, of which 50% led to a TAVR, 39% were off-listed for other reasons, and 11% remained on the wait list at the conclusion of the study. For patients who underwent a TAVR, the estimated median wait time in the postreimbursement period stabilized at 80 days and has remained unchanged. The cumulative probability of wait-list mortality and heart failure hospitalization at 80 days was ≈2% and 12%, respectively, with a relatively constant increase in events with increased wait times. CONCLUSIONS: Postreimbursement wait time has remained unchanged for patients undergoing a TAVR procedure, suggesting the increase in capacity has kept pace with the increase in demand. The current wait time of almost 3 months is associated with important morbidity and mortality, suggesting a need for greater capacity and access.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Elbaz-Greener G, Masih S, Fang J, et al. Temporal Trends and Clinical Consequences of Wait Times for Transcatheter Aortic Valve Replacement: A Population-Based Study. Circulation. 2018. PMID: 29511000. doi:10.1161/CIRCULATIONAHA.117.033432

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。